US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking a strategic expansion in the world’s second-largest biotech market. The Shanghai plant, with a Phase 1 investment of RMB 50 million (USD 7.2 million), aims to localize production of high-end gene sequencers and consumables over the next five years, with total investment reaching RMB 450 million (USD 65.5 million).
Manufacturing Details
The facility adopts global quality standards and intelligent production processes. Phase 1 will focus on manufacturing 16 clinical sequencing reagents, with the first products set for delivery by year-end. The move follows Illumina’s upgrades to its Greater China headquarters and logistics centers, supported by China’s favorable industry policies.
Global Presence
Illumina, which holds 83.9% of the global gene sequencing market, also operates plants in the US and Singapore. The Shanghai base underscores its commitment to China’s booming biopharma sector, where demand for localized sequencing solutions is rising.-Fineline Info & Tech
